Practical patient care appraisals with use of new potassium binders in heart failure and chronic kidney diseases
Copyright © 2023 Italian Federation of Cardiology - I.F.C. All rights reserved..
Hyperkalaemia is a life-threatening condition leading to significant morbidity and mortality. It is common in heart failure and in chronic kidney disease (CKD) patients due to the diseases themselves, which often coexist, the high co-presence of diabetes, the fluctuations in renal function, and the use of some drugs [i.e. renin-angiotensin-aldosterone system (RAAS) inhibitors]. Hyperkalaemia limits their administration or uptitration, thus impacting on mortality. New K + binders, namely patiromer and sodium zirconium cyclosilicate (ZS-9), are an intriguing option to manage hyperkalaemia in heart failure and/or CKD patients, both to reduce its fatal effects and to let clinicians uptitrate RAAS inhibition. Even if their real impact on strong outcomes is still to be determined, we hereby provide a practical approach to favour their use in routine clinical practice in order to gain the correct confidence and provide an additive tool to heart failure and CKD patients' wellbeing. New trials are welcome to fill the gap in knowledge.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Journal of cardiovascular medicine (Hagerstown, Md.) - 24(2023), 11 vom: 01. Nov., Seite 781-789 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Senni, Michele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 02.10.2023 Date Revised 02.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2459/JCM.0000000000001555 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361930690 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361930690 | ||
| 003 | DE-627 | ||
| 005 | 20231226090202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2459/JCM.0000000000001555 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM361930690 | ||
| 035 | |a (NLM)37695628 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Senni, Michele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Practical patient care appraisals with use of new potassium binders in heart failure and chronic kidney diseases |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2023 | ||
| 500 | |a Date Revised 02.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Italian Federation of Cardiology - I.F.C. All rights reserved. | ||
| 520 | |a Hyperkalaemia is a life-threatening condition leading to significant morbidity and mortality. It is common in heart failure and in chronic kidney disease (CKD) patients due to the diseases themselves, which often coexist, the high co-presence of diabetes, the fluctuations in renal function, and the use of some drugs [i.e. renin-angiotensin-aldosterone system (RAAS) inhibitors]. Hyperkalaemia limits their administration or uptitration, thus impacting on mortality. New K + binders, namely patiromer and sodium zirconium cyclosilicate (ZS-9), are an intriguing option to manage hyperkalaemia in heart failure and/or CKD patients, both to reduce its fatal effects and to let clinicians uptitrate RAAS inhibition. Even if their real impact on strong outcomes is still to be determined, we hereby provide a practical approach to favour their use in routine clinical practice in order to gain the correct confidence and provide an additive tool to heart failure and CKD patients' wellbeing. New trials are welcome to fill the gap in knowledge | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Potassium |2 NLM | |
| 650 | 7 | |a RWP5GA015D |2 NLM | |
| 700 | 1 | |a Sciatti, Edoardo |e verfasserin |4 aut | |
| 700 | 1 | |a Bussalino, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a D'Elia, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a Ravera, Maura |e verfasserin |4 aut | |
| 700 | 1 | |a Paoletti, Ernesto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiovascular medicine (Hagerstown, Md.) |d 2006 |g 24(2023), 11 vom: 01. Nov., Seite 781-789 |w (DE-627)NLM162293844 |x 1558-2035 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:781-789 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2459/JCM.0000000000001555 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 11 |b 01 |c 11 |h 781-789 | ||